Seelos Therapeutics (SEELQ) 8-K Other Events

Apricus Biosciences, Inc. (NASDAQ:APRI)

Corporate Presentation

BIO

CEO

&

Investor

Conference

–

New

York

City

Tuesday February 12, 2013

1

Exhibit 99.1

Safe-Harbor Statement

2

Statements

under

the

Private

Securities

Litigation

Reform

Act,

as

amended:

With

the

exception

of

the

historical

information

contained

in

this

presentation,

the

matters

described

herein

contain

forward-looking

statements

that

involve

risks

and

uncertainties

that

may

individually,

mutually,

or

materially

impact

the

matters

herein

described.

These

forward-looking

statements

include,

but

are

not

limited

to:

the

ability

to

obtain

regulatory

approval

for

Vitaros

in

Europe

and

other

markets

in

the

time

frames

estimated,

if

at

all;

the

ability

to

successfully

develop

other

products in

clinical

development,

including

a

room-temperature

formulation

of

Vitaros

and

Femprox;

our

ability

to

enter

into

new

licenses

and

partnering

agreements;

our

ability

to

realize

revenue

under

existing

license

agreements;

and

our

ability

to

successfully

commercialize

Vitaros.

Attendees

and

readers

of

these

materials

are

cautioned

not

to

place

undue

reliance

on

these

forward-looking

statements

as

actual

results

could

differ

materially

from

the

forward-looking

statements

contained

herein.

Attendees

and

readers

of

these

materials

are

urged

to

read

the

risk

factors

set

forth

in

the

Company’s

most

recent

annual

report

on

Form

10-K,

subsequent

quarterly

reports

filed

on

Form

10-Q

and

its

most

recent

SEC

filings

for

additional

risks

and

considerations

that

could

cause

actual

results

to

differ

materially

from

expected

results.

Company

disclaims

any

intention

to

update

this

presentation

to

reflect

actual

subsequent

events.

Company Highlights -

NASDAQ (APRI)

•

Apricus Bio (Nasdaq: APRI) is a pharmaceutical company that develops and

markets pharmaceutical products that help large patient populations primarily in

the area of sexual health

•

Lead Products / Product Candidates:

•

Vitaros ®

-

Topical Treatment for Erectile Dysfunction

–

Approved in Canada for entire ED patient population & awaiting approval

decision in Europe

•

Femprox®

-

Topical Treatment for Female Sexual Arousal Disorder

–

Completed one successful Phase III trial in China and moving towards

additional late-stage trials

•

The Company has commercial partnerships with multiple large pharmas (Abbott,

Takeda, Sandoz, Warner Chilcott and Bracco)

•

The

Company

is

focused

on

(1)

establishing

new

Vitaros®

partnerships

in

the

territories available for licensing and (2) developing and licensing Femprox®

throughout the world

3

Upcoming Expected Milestones

Commence sales of Vitaros®

in Canada by Abbott (H1 2013)

Vitaros®

approval decision in Europe (H1 2013)

Approval decision in Switzerland, other territories (2013)

Additional Vitaros partnerships for the emerging markets

(H1 2013)

Femprox®

regulatory and clinical design plan

communicated (H1 2013)

4

Leading Commercial

& Development Partners

5

Partnerships throughout the world for Vitaros®

Vitaros®

6

•

Vitaros®

(alprostadil/DDAIP.HCl) for the treatment of erectile dysfunction

•

Significant efficacy, including difficult to treat populations

•

Approved in Canada (H1 2013 launch)

•

Filed

in

Europe

using

DCP

–

potential

approval

expected

H1

2013

•

Potential CRL response to US FDA (via Warner Chilcott)

•

Patent coverage thru 2031

•

Seeking commercial partners: Latin America, select EU countries,

Russia, Japan

Second

Generation

RT Available

in 2014

•

Cold

Chain

(2

C

-

8

C)

•

7 Days Room Temp

•

Room Temperature

•

Expected 24-36 month shelf life

–

Rapid onset (generally 5-15 minutes)

–

Studied in over 3,300 patients

–

Diabetics, hypertensives, patients with cardiac issues or on nitrates/alpha

blockers, prostatectomy patients, Sildenafil (Viagra®) failures

Vitaros®

-

Target Patient Population

Want a faster acting and on-demand   

treatment

Patients who prefer a locally acting treatment

instead of an oral treatment

Are contraindicated due to medications or

concurrent diseases (18%¹)

Are healthy enough to take the PDE5 inhibitors

but quit taking them because they are non-

responders (20%

1,3

) and

Drop out after initial prescription (31%²) or

drop out after 3 years from start (48%²)

7

(Present Existing Market)

$2.6B Ex-US

1.

D2 Market Research, June 2007

2.

Sato Y et al, How long do patients with erectile dysfunction continue to use sildenafil citrate?  International Journal of Urology. (2007) 14, 339-342

3.

Carvalheira AA, Pereira NM, Maroco J, and Forjaz V. Dropout in the treatment of erectile dysfunction with PDE5: A study on predictors and a

qualitative analysis of reasons for discontinuation. J Sex Med 2012;9:2361–2369

ED Market Segmentation

51%

18%

20%

11%

PDE5 Market

Contraindicated Patients

Non-Responders

Other Dropouts

Vitaros is a non-PDE-5 treatment for patients

who:

Femprox

•

Femprox

®

(alprostadil/DDAIP.HCl) intended for the treatment of female

sexual arousal disorder (FSAD)

•

FSAD affects as many as 10M women in the US and is different than

Female Sexual Dysfunction

•

Achieved statistically significant efficacy in primary and secondary

endpoints with favorable safety and tolerability

•

No product currently approved in the US for FSAD

•

Regulatory guidance meetings (US FDA, Europe, Canada) on-going

•

Apricus to provide planned regulatory and clinical path for US, Canada, and

European markets in H1 2013

•

Patent coverage through 2031

•

Seeking global commercial partner

8

•

Seven clinical studies completed to date, including one, 98-patient

Phase II study in the U.S. and a 400-patient Phase III study in China

Femprox®

Phase III Study

•

A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Study

of

the

Efficacy

and

Safety

of

Alprostadil

Cream

in

Patients

with

Female

Sexual Arousal Disorder (FSAD) in China

o

n=

400

patients

placebo,

500,

700

or

900

mcg

alprostadil

cream

groups,

Application sites: clitoris and the distal anterior vaginal wall

o

Five (5) month study

9

Market Potential of Top Pipeline Products

•

Vitaros®

–

Ex-US market potential for ED: $2.5-3.0B

•

Europe: $1B+

•

Canada: $180M

–

First-line treatment for entire patient population

including non-PDE5 patients

•

Femprox®

–

Worldwide market potential: $2-4B

–

Potential to be the first drug approved for FSAD

10

Financial Snapshot

11

•

NASDAQ:

APRI

•

Operations

in:

San

Diego,

California

Montigny,

France

(near

Paris)

•

Employees

:

~120

•

Shares

outstanding

:

29.9M*

•

Shares

fully

-diluted:

35.7M*

•

Cash

position

:

$15.0M*

•

Share-price:

$3.34

†

•

Market

Cap:

$99.9M

†

†

As of February 8, 2013

*As of December 31,  2012

Summary

•

Apricus Bio (Nasdaq: APRI) is a pharmaceutical company that develops and

markets pharmaceutical products that help large patient populations primarily in

the area of sexual health

•

Lead Products / Product Candidates:

•

Vitaros

®

-

Topical

Treatment

for

Erectile

Dysfunction

–

Approved in Canada for entire ED patient population & awaiting approval

decision in Europe

•

Femprox®

-

Topical

Treatment

for

Female

Sexual

Arousal

Disorder

–

Completed one successful Phase III trial & planning for second Phase III trial

•

The Company has commercial partnerships with multiple large pharmas

(Novartis, Abbott, Sandoz, Takeda, Warner Chilcott and Bracco)

•

The

Company

is

focused

on

(1)

establishing

new

Vitaros®

partnerships

in

the

territories available for licensing and (2) developing and licensing Femprox®

throughout the world

12

Apricus Biosciences, Inc.

11975 El Camino Real, Suite 300 –

San Diego, CA 92130

Phone: (858)-222-8041

13

For further information, please contact:

Mr. Edward Cox

Vice President, Corporate Development & Investor Relations

Email: ECox@ApricusBio.com